{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:51:52Z","timestamp":1782885112966,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111849","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:35:46Z","timestamp":1782880546000},"source":"Crossref","is-referenced-by-count":0,"title":["Probable Vildagliptin-Associated Acute Pancreatitis in a Patient With Well-Controlled Type 2 Diabetes Mellitus: A Case Report"],"prefix":"10.7759","author":[{"given":"Kyaw Zin","family":"Aung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naw Eh Law","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks PA","year":"2013","unstructured":"Banks PA, Bollen TL, Dervenis C, et al.. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013, 62:102-111. 10.1136\/gutjnl-2012-302779","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002645","article-title":"American College of Gastroenterology guidelines: management of acute pancreatitis","volume":"119","author":"Tenner S","year":"2024","unstructured":"Tenner S, Vege SS, Sheth SG, et al.. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024, 119:419-437. 10.14309\/ajg.0000000000002645","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.023","article-title":"Drug-induced acute pancreatitis: an evidence-based review","volume":"5","author":"Badalov N","year":"2007","unstructured":"Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007, 5:648-661. 10.1016\/j.cgh.2006.11.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon CF","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020, 16:642-653. 10.1038\/s41574-020-0399-8","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs--FDA and EMA assessment","volume":"370","author":"Egan AG","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014, 370:794-797. 10.1056\/NEJMp1314078","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12176","article-title":"Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami M","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014, 16:48-56. 10.1111\/dom.12176","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.015","article-title":"Pancreatitis and pancreatic cancer risk among patients with type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors: an updated meta-analysis of randomized controlled trials","volume":"46","author":"Tuersun A","year":"2024","unstructured":"Tuersun A, Hou G, Cheng G. Pancreatitis and pancreatic cancer risk among patients with type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors: an updated meta-analysis of randomized controlled trials. Clin Ther. 2024, 46:650-656. 10.1016\/j.clinthera.2024.06.015","journal-title":"Clin Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-012-0245-9","article-title":"Drug-induced pancreatitis","volume":"14","author":"Nitsche C","year":"2012","unstructured":"Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. Curr Gastroenterol Rep. 2012, 14:131-138. 10.1007\/s11894-012-0245-9","journal-title":"Curr Gastroenterol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler AE","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013, 62:2595-2604. 10.2337\/db12-1686","journal-title":"Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231883","article-title":"Drug induced pancreatitis: a systematic review of case reports to determine potential drug associations","volume":"15","author":"Wolfe D","year":"2020","unstructured":"Wolfe D, Kanji S, Yazdi F, et al.. Drug induced pancreatitis: a systematic review of case reports to determine potential drug associations. PLoS One. 2020, 15:e0231883. 10.1371\/journal.pone.0231883","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506622-probable-vildagliptin-associated-acute-pancreatitis-in-a-patient-with-well-controlled-type-2-diabetes-mellitus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:35:56Z","timestamp":1782880556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506622-probable-vildagliptin-associated-acute-pancreatitis-in-a-patient-with-well-controlled-type-2-diabetes-mellitus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.111849","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}